Arja Jukkola-Vuorinen

List of Publications by Year
in descending order

56	4,947	236925 25	168389 53
papers	citations	h-index	g-index

58	58	58	8892
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
2	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
3	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
4	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
5	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
6	Aberrant type I and type III collagen gene expression in human breast cancerin vivo. Journal of Pathology, 1998, 186, 262-268.	4.5	216
7	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
8	Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocrine-Related Cancer, 2004, 11, 571-579.	3.1	122
9	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
10	Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial. Journal of Clinical Oncology, 2012, 30, 11-18.	1.6	114
11	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	12.8	105
12	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	6.2	76
13	Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer. JAMA Oncology, 2017, 3, 793.	7.1	74
14	Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology, The, 2009, 10, 1145-1151.	10.7	65
15	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
16	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	2.5	49
17	Longâ€term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer. Clinical Endocrinology, 2018, 88, 303-310.	2.4	47
18	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	1.9	45

#	Article	IF	Citations
19	CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer. Scientific Reports, 2021, 11, 6035.	3.3	42
20	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	3.5	39
21	KEAP1 Genetic Polymorphisms Associate with Breast Cancer Risk and Survival Outcomes. Clinical Cancer Research, 2015, 21, 1591-1601.	7.0	37
22	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	6.2	37
23	CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population. BMC Cancer, 2017, 17, 620.	2.6	29
24	Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study. BMC Cancer, 2017, 17, 72.	2.6	27
25	Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer. Clinical Breast Cancer, 2019, 19, e522-e533.	2.4	27
26	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	5.0	26
27	High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer. BMC Cancer, 2018, 18, 223.	2.6	25
28	USP28 Deficiency Promotes Breast and Liver Carcinogenesis as well as Tumor Angiogenesis in a HIF-independent Manner. Molecular Cancer Research, 2018, 16, 1000-1012.	3.4	23
29	Targeted Next-Generation Sequencing Identifies a Recurrent Mutation in MCPH1 Associating with Hereditary Breast Cancer Susceptibility. PLoS Genetics, 2016, 12, e1005816.	3.5	22
30	Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer. Anticancer Research, 2016, 36, 6431-6438.	1.1	21
31	Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility. Scientific Reports, 2017, 7, 681.	3.3	20
32	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
33	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nature Communications, 2014, 5, 4051.	12.8	16
34	Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. International Journal of Clinical Oncology, 2016, 21, 231-239.	2.2	15
35	Rare missense mutations in RECQL and POLG associate with inherited predisposition to breast cancer. International Journal of Cancer, 2018, 142, 2286-2292.	5.1	15
36	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	5.0	14

#	Article	IF	Citations
37	Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. Journal of Clinical Oncology, 2022, , JCO2102054.	1.6	14
38	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 2016, 11, e0160316.	2.5	12
39	High baseline Tie1 level predicts poor survival in metastatic breast cancer. BMC Cancer, 2019, 19, 732.	2.6	12
40	Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital. BMJ Open, 2020, 10, e038798.	1.9	12
41	Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study. Acta OncolÃ³gica, 2020, 59, 1110-1117.	1.8	12
42	Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo. Oncotarget, 2016, 7, 87373-87389.	1.8	11
43	High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study. Frontiers in Oncology, 2020, 10, 1470.	2.8	10
44	Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. Breast Cancer Research and Treatment, 2019, 175, 741-748.	2.5	9
45	Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A. Oncology, 2019, 96, 147-155.	1.9	7
46	Cytoplasmic Mineralocorticoid Receptor Expression Predicts Dismal Local Relapse-free Survival in Non-triple-negative Breast Cancer. Anticancer Research, 2019, 39, 5879-5890.	1.1	6
47	Elevated preoperative serum levels of collagen I carboxyterminal telopeptide predict better outcome in early-stage luminal-B-like (HER2-negative) and triple-negative subtypes of breast cancer. Tumor Biology, 2019, 41, 101042831984708.	1.8	5
48	Association of Metformin, Other Antidiabetic Medications, and Statins With Incidence of Colon Cancer in Patients With Type 2 Diabetes. Clinical Colorectal Cancer, 2021, 20, e113-e119.	2.3	5
49	Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes. Scientific Reports, 2021, 11, 10445.	3.3	5
50	Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial.. Journal of Clinical Oncology, 2016, 34, 1001-1001.	1.6	3
51	Early progression of breast cancer during neoadjuvant chemotherapy may predict poorer prognoses. Acta OncolÃ³gica, 2020, 59, 1036-1042.	1.8	2
52	Real-world, single-centre prospective data of age at breast cancer onset: focus on survival and reproductive history. BMJ Open, 2021, 11, e041706.	1.9	2
53	Aberrant type I and type III collagen gene expression in human breast cancer in vivo. , 1998, 186, 262.		2
54	Radiological and pathological assessment of response to neoadjuvant CDK4/6 inhibitor and endocrine treatments in a real-life settingâ€"initial results. Acta Radiologica Open, 2021, 10, 205846012110306.	0.6	1

#	Article	IF	Citations
55	Early-Life Risk Factors for Breast Cancer â€“ Prospective Follow-up in the Northern Finland Birth Cohort 1966. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 616-622.	2.5	0
56	How breast cancer recurrences are found â€“ a real-world, prospective cohort study. Acta OncolÃ³gica, 2022, 61, 417-424.	1.8	0